No investment advice!
I do this only for practicing.
I see a cup and handle
Very nice risk / reward here.
Upcoming Catalysts:
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)
Phase 2
Mid-2021
Phase 2 top-line change in liver fat data met primary endpoint January 12, 2021. 36-week biopsy data are expected mid-2021.
I do this only for practicing.
I see a cup and handle
Very nice risk / reward here.
Upcoming Catalysts:
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)
Phase 2
Mid-2021
Phase 2 top-line change in liver fat data met primary endpoint January 12, 2021. 36-week biopsy data are expected mid-2021.
Trade closed: stop reached:
SL hit